Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a).
Journal: Journal of the American College of Cardiology
Published: June 15, 2026
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). Reply.
Journal: The New England journal of medicine
Published: July 23, 2025
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).
Journal: The New England journal of medicine
Published: March 31, 2025
Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis.
Journal: Journal of the American Heart Association
Published: March 13, 2025
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.
Journal: JAMA
Published: November 18, 2024
Patient-centered assessment of treatment for alpha-1 antitrypsin deficiency: literature review to identify concepts and measures for people with alpha1-antitrypsin deficiency.
Journal: Orphanet journal of rare diseases
Published: October 17, 2024
Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin.
Journal: Journal of lipid research
Published: August 28, 2024
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
Journal: The journal of headache and pain
Published: December 19, 2023
Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
Journal: Cephalalgia : an international journal of headache
Published: March 23, 2023
Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
Journal: Cephalalgia : an international journal of headache
Published: August 18, 2022
Last Updated: 09/26/2026